HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HBW Legislative News: Another Federal CR, Michigan On DXM List, Senators Say Supplements Are 'Medical Expenses'

Executive Summary

Federal agencies at FY 2019 funding for another month; Michigan imposes age restriction on OTC DXM sales; and senators urge IRS to make supplements 'medical expenses'.

You may also be interested in...

Another State Age-Restricts Sales Of DXM OTC Drugs As Teens' Abuse Of Ingredient Grows

Percentage of 10th- and 12th-graders in MTF survey using DXM-containing OTCs for inebriation effects had declined while rate of 8th-graders increased from 2018 to 2019. However, abuse of OTC drugs containing the cough suppressant increased in all age groups in 2020 survey.

Manufacturers Consider Design Changes For OTC Propylhexedrine Nasal Decongestant Inhalers

"Manufacturers are already working on possible solutions to address the concerns and will work with the Agency to implement any appropriate measures,” says CHPA senior VP  Barbara Kochanowski.

Propylhexedrine Abuse Prompts US FDA To Suggest OTC Nasal Inhaler Modifications, Smaller Size

FDA published warning against abuse of propylhexedrine, but study published in October 2020 questioned why sales of products with the ingredient aren’t limited like sales of pseudoephedrine-containing OTCs under a federal law.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts